Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (1230)	1/6/2007 9:27:06 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 1336

That's very nice of you to say, thanks! ........................ Tuck follows the tool companies, I need to go back and read some of his stuff. Obviously clinical diagnostics and biomarkers and all that are a hot area--personalized medicine, or the dream of it. Surrogate markers too--for instance (I have to give an example from one of the very few companies I follow, Infinity) I think PET scans go along with the dosing of IPI-504 to show activity. Markers of disease response go along with smarter clinical endpoints and all that stuff. I'm a real numbskull--the puzzle only very slowly comes together for me. If you found something on that old thread that looked good, I was probably impersonating wisdom. And if you post a lot, some of your stuff looks good. But a lot of my stuff is pretty weak. But it is fun to think out loud, and I type fast. Anyway, help me figure out why ILMN and SQNM did so well the past year. Nobody likes tool companies, what is up with that.